Biobillionair Tuesday, 02/12/19 08:51:35 AM Re: SocialBoom post# 175769 0 Post # of 177248 SB-Every BP with a cardiovascular team "needs" Vascepa and Amarin. GILD is no different from a PFE, AZN, GSK, MRK or a long list of others.... This doesn't change the fact that Amarin doesn't need to sell and the Vascepa cardiovascular program is NOW GREATLY de-risked. As a drug candidate is de-risked any would be suitor is going to pay closer to retail. Here's the biggest problem with Amarin M&A: DEFINING RETAIL VALUE OF VASCEPA!!! I don't think the Vascepa market can be properly defined until at least 2 full years of sales with cardiovascular treatment label for Vascepa. An M&A will have to contain milestone CVRs based on future sales....Any and ALL of the above BP's can do this deal. Any M&A deal will be either MASSIVE (bidding war) or a long negotiated complex CVR. (long because of the number of interested parties) My point.....Don't hold your breath on a massive bidding war and huge BO price...I think it will be a complex CVR and likely not anytime soon. Amarin is going to launch Vascepa into cardiovascular market and perhaps grow into the next GILD. BB I do not pump Amarin stock. I am not an Amarin cheerleader. If I see something I don't like I make it known. Patients come first, always!!!